Latest KFF Health News Stories
How a Duty To Spend Wisely on Worker Benefits Could Loosen PBMs’ Grip on Drug Prices
As criticism of pharmacy benefit managers heats up, fear of lawsuits is driving some big employers to drop the “Big Three” PBMs — or force them to change.
Readers Embrace ‘Going It Alone’ Series on Aging and Chastise Makers of Pulse Oximeters
KFF Health News gives readers a chance to comment on a recent batch of stories.
Florida Gov. DeSantis’ Canadian Drug Import Plan Goes Nowhere After FDA Approval
Florida sued the FDA over what it said was a “reckless delay” in approving its drug importation plan. Now, nearly a year after the FDA gave the state the green light, the program has yet to begin.
El plan del gobernador de Florida para importar medicamentos más baratos de Canadá sigue en la nada
Florida solicitó crear un programa de importación en noviembre de 2020, pocos meses después que la administración Trump concediera esta opción a los estados.
Listen: A Tussle With a Rattlesnake Can Take a Bite Out of Your Wallet
Listen to KFF Health News’ Jackie Fortiér recount how a backyard snakebite led to a harrowing hospitalization — and big bills — for a San Diego family.
What’s at Stake: A Pivotal Election for Six Big Health Issues
Health care has ebbed and surged as an election issue throughout the presidential campaign. Here are the ways some of the most consequential changes in health policies could hinge on whether Vice President Kamala Harris or former President Donald Trump wins.
PBM Math: Big Chains Are Paid $23.55 To Fill a Blood Pressure Rx. Small Drugstores? $1.51.
Criticism of prescription drug middlemen has intensified recently in the wake of a federal agency’s actions and legislative reform attempts. Georgia Republican Gov. Brian Kemp, though, vetoed a related bill that would have helped independent pharmacies, citing the unfunded cost of the move.
Beneficiarios de Medicare gastarán menos en medicamentos en 2025
El período de inscripción anual para que los beneficiarios de Medicare renueven o cambien su cobertura de medicamentos, o elijan un plan Medicare Advantage, comenzó el 15 de octubre y se extiende hasta el 7 de diciembre.
Medicare Drug Plans Are Getting Better Next Year. Some Will Also Cost More.
Every year, Medicare officials encourage beneficiaries to shop around for their drug coverage. Few take the time. This year, it might be more important than ever.
KFF Health News' 'What the Health?': Yet Another Promise for Long-Term Care Coverage
As part of her presidential campaign, Vice President Kamala Harris has rolled out a plan for Medicare to provide in-home long-term care services. The proposal would fill a longtime need for families trying to simultaneously care for young children and older parents, but its enormous price tag makes it a promise unlikely to be fulfilled. Meanwhile, a growing number of Republican candidates up and down the ballot facing voter backlash over their support for abortion restrictions are trying to reinvent their positions. Shefali Luthra of The 19th, Jessie Hellmann of CQ Roll Call, and Joanne Kenen of Johns Hopkins University and Politico join KFF Health News’ Julie Rovner to discuss these stories and more. Also this week, excerpts from a KFF lunch with “Shark Tank” panelist and generic drug discounter Mark Cuban, who has been consulting with the Harris campaign about health care issues.
Employers Haven’t a Clue How Their Drug Benefits Are Managed
The Big Three pharmacy benefit managers say they return nearly all the rebates they get from drugmakers to the employers and insurers who hire them. But most employers seem to doubt that.
Calif. Ballot Measure Targets Drug Discount Program Spending
Californians in November will weigh in on a ballot initiative to increase scrutiny over the use of health-care dollars — particularly money from a federal drug discount program — meant to support patient care largely for low-income or indigent people. The revenue is sometimes used to address housing instability and homelessness among vulnerable patient populations. Voters […]
KFF Health News' 'What the Health?': The Health of the Campaign
The 2024 presidential race is taking on a familiar tone — with Democrats accusing Republicans of wanting to ban abortion and repeal the Affordable Care Act and Republicans insisting they have no such plans. Voters will determine whom they believe. Meanwhile, for the second time in a month, a state judge overturned an abortion ban, but few expect the decision to settle the matter. Alice Miranda Ollstein of Politico, Sandhya Raman of CQ Roll Call, and Anna Edney of Bloomberg News join KFF Health News chief Washington correspondent Julie Rovner to discuss these stories and more. Also this week, Rovner interviews KFF Health News’ Lauren Sausser, who reported and wrote the latest KFF Health News-Washington Post “Bill of the Month,” about a teenage athlete whose needed surgery lacked a billing code.
Harris Correct That Trump Fell Short on Promise To Negotiate Medicare Drug Prices
The former president instead favored a temporary model that could’ve brought down prices of some prescription drugs, but it was blocked by the courts.
KFF Health News' 'What the Health?': Congress Punts to a Looming Lame-Duck Session
Congress left Washington for the campaign trail this week, but not before approving a spending bill that expires shortly before Christmas. Lawmakers will be busy after the election working on not just the legislation needed to keep the government running, but also several health programs set to expire. Meanwhile, Republicans continue to downplay abortion as Democrats press it as a campaign issue. Alice Miranda Ollstein of Politico, Lauren Weber of The Washington Post, and Joanne Kenen of Johns Hopkins University and Politico join KFF Health News chief Washington correspondent Julie Rovner to discuss these stories and more.
KFF Health News' 'What the Health?': American Health Under Trump — Past, Present, and Future
Dreaming of a Trump victory, Republicans have a wish list of health policy changes — including loosening Affordable Care Act regulations to make cheaper coverage available and ending Medicare drug price negotiations. Meanwhile, after a publicly reported death stemming from a state abortion ban, Vice President Kamala Harris is emphasizing the consequences of Trump’s work to overturn Roe v. Wade. Tami Luhby of CNN, Shefali Luthra of The 19th, and Joanne Kenen of Politico and Johns Hopkins University join KFF Health News senior editor Emmarie Huetteman to discuss these stories and more.
California May Regulate and Restrict Pharmaceutical Brokers
California lawmakers are moving to rein in the pharmaceutical middlemen they say drive up costs and limit consumers’ choices. The bill sent to Gov. Gavin Newsom would require pharmacy benefit managers to be licensed in California and would ban some business practices. Newsom vetoed a previous effort three years ago.
Harris and Trump Are Ready To Take on Big Pharma
Former president Donald Trump and Vice President Kamala Harris are both eager to take on high drug prices, leaving pharmaceutical companies on the defensive as they spend millions of dollars this election season. When Harris was California’s attorney general, she joined cases that resulted in almost $7.2 billion (about $22 per person in the United […]
With TV Drug Ads, What You See Is Not Necessarily What You Get
The pharmaceutical industry has invented a new art form: finding ways to make their wares seem like joyous must-have treatments, while often minimizing lackluster efficacy and risks.
En los comerciales de medicamentos en TV, lo que ves no siempre es lo que es
Los anuncios de medicamentos han sido omnipresentes en la televisión desde finales de la década de 1990 y se han extendido a internet y las redes sociales. Pocas naciones en el mundo los permiten
